• Áreas Terapéuticas
  • Productos
    • Indicaciones
  • Profesionales Sanitarios
Homekeyboard_arrow_rightApalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
Apalutamide, Darolutamide and Enzalutamide for nmCRPC
Ir al contenido
Oncología

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review

Cattrini, C.; Caffo, O. et al.Cancers 2022, 14, 1792. https://doi.org/10.3390/cancers14071792

Contenido relacionado